Tech Company Financing Transactions
Beam Therapeutics Funding Round
Sixth Street Partners participated in a $500 million funding round for Beam Therapeutics. The round closed on 2/24/2026.
Transaction Overview
Company Name
Announced On
2/24/2026
Transaction Type
Venture Equity
Amount
$500,000,000
Round
Undisclosed
Investors
Sixth Street Partners (Jeff Pootoolal)
Proceeds Purpose
This strategic financing provides Beam with significant flexibility and long-term, non-dilutive capital to support the anticipated commercial launch and subsequent revenue generation for risto-cel, which we believe has the potential to be a best-in-class, one-time treatment for sickle cell disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
26 Landsdowne St. 2nd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Beam Therapeutics is pioneering the use of CRISPR base editing to develop precision genetic medicines that treat disease, one letter at a time.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Evans
Chief Scientific Officer
Giuseppe Ciaramella
Co-Founder
Keith Joung
Co-Founder
David Liu
Co-Founder
Feng Zhang
Vice President
Francine Gregoire
Vice President
Dana Levasseur
VP - Bus. Development
Courtney Wallace
VP - Finance
Suzanne Fleming
Browse more venture capital transactions:
Prev: 2/24/2026: Nimble Way venture capital transaction
Next: 2/24/2026: Based venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs